Skip to content

Secukinumab in TNF-IR Psoriasis Patients

Secukinumab in TNF-IR Psoriasis Patients 1

Summary. This study is designed to prove and quantify the hypothesis that secukinumab is effective, safe and well tolerated in the treatment of moderate to severe chronic plaque-type psoriasis in patients who are inadequate responders to anti-TNF therapy in a UK (and Republic of Ireland) specific population. This study is designed to prove and quantify the hypothesis that secukinumab is effective, safe and well tolerated in the treatment of moderate to severe chronic plaque-type psoriasis in patients who are inadequate responders to anti-TNF therapy in a UK (and Republic of Ireland) specific population. Keywords: interleukin-17A, methotrexate, rheumatoid arthritis, secukinumab. Patients with inadequate responses to initial TNF blocker therapy are often switched to a second TNF blocker or a biologic with an alternative mechanism. In contrast, Th17 and IL-17A levels increased significantly in patients with a TNF-IR, although TNF levels declined.

Secukinumab in TNF-IR Psoriasis Patients 2Secukinumab was generally well tolerated by the patients with a safety profile consistent with that observed in the psoriasis and psoriatic arthritis clinical trial programs. In patients with psoriasis, serum levels of total IL-17A (free and secukinumab-bound IL-17A) increase to plateau serum concentrations after administration of secukinumab. No results, but try the following: Secukinumab in TNF IR Psoriasis Patients in PubMed EuropePMC.

Cosentyx(TM) (secukinumab) data to be revealed in patients with difficult-to-treat psoriasis of the palms, soles and nails at World Congress of Dermatology (WCD). Additionally, new data on Cosentyx(TM) (secukinumab) in difficult-to-treat psoriasis of the palms, soles and nails, and on Xolair (omalizumab) in Chronic Spontaneous Urticaria, will be presented at the 23rd World Congress of Dermatology (WCD), from 8-13 June in Vancouver, Canada. FUTURE 2: Secukinumab improved signs and symptoms of psoriatic arthritis in both anti-TNF-naive and anti-TNF-IR patients. Keywords: Anti-TNF therapy and psoriatic arthritis, Biologic agents. Signs and Symptoms of Active Psoriatic Arthritis in Anti-TNF-Naive Patients and Those Previously Exposed to Anti-TNF Therapy: 52-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Dosing. Late-breaking: Secukinumab effective in patients with nail psoriasis: 16 week results from the TRANSFIGURE study. FUTURE 2: Secukinumab improved signs and symptoms of psoriatic arthritis in both anti-TNF-naive and anti-TNF-IR patients.

Six Swiss Exchange

Psoriasis Treatment Center of Central New Jersey, East Windsor, NJ 3Major finding: The PASI 75 response rate at 12 weeks in patients with moderate to severe chronic plaque psoriasis was 77.

Six Swiss Exchange